Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that baricitinib was effective and well tolerated for long-term scalp hair regrowth in severe alopecia areata patients, with certain predictors identified for treatment response.

This study found that escalating baricitinib to 6 mg daily improved hair loss in 75% of patients with severe refractory alopecia areata who responded poorly to standard treatments, while also noting manageable short-term safety concerns under close monitoring.

This study suggests that off-label use of baricitinib in children under 12 with alopecia areata may improve hair regrowth, but further research is needed to confirm efficacy and safety.

In a randomized controlled trial, King et al. found that oral baricitinib at doses of 2 mg and 4 mg significantly improved hair regrowth in adults with alopecia areata compared to placebo, supporting its efficacy and safety for those with substantial scalp hair loss.

In this study, baricitinib 4 mg led to greater scalp, eyebrow, and eyelash hair regrowth in severe alopecia areata patients than baricitinib 2 mg at weeks 36 and 52.

This study found that dermoscopic indicators like black dots and tapering hairs are valuable markers for diagnosing and assessing the severity and activity of alopecia areata in Asian patients.

This study found that specific dermoscopic markers, including yellow dots and black dots, are associated with poor prognosis in alopecia areata patients, while vellus hair indicates a more favorable outcome.

This study reports promising preliminary trends in the safety and efficacy of a botanical drug candidate for pediatric alopecia areata, but conclusive results are not yet available.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

This consensus provides a framework for standardized diagnosis and treatment of alopecia areata in the Asia Pacific region, recommending specific therapies based on age and disease severity.

This study suggests that monitoring CD8+ TEMRA cells in patients with rapidly progressive alopecia areata treated with intravenous corticosteroids could help predict therapeutic outcomes.

This study reports that two phase III trials demonstrated the effectiveness of the oral Janus kinase inhibitor baricitinib at 2 mg or 4 mg daily for treating severe alopecia areata in adults, marking a potential advance in managing this condition.

This study found that the SAAD-41 is a validated tool for assessing psychosocial outcomes in individuals with alopecia areata, showing strong correlations with established measures of quality of life and coping.

This review discusses various treatments for alopecia areata, highlighting their limitations and individualized approach, and reports no new clinical results.

In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.

This study introduced and validated the VESALT, a visual extension of the Severity of Alopecia Tool, finding it offers improved reliability and user-friendliness over SALT by incorporating pattern recognition and broader coverage, including non-scalp regions, in assessing alopecia areata severity.

This study found that yellow dots seen under dermatoscopy are a sensitive and specific indicator of treatment response in alopecia areata, showing significant reduction as early as four weeks.

This case report describes a child with alopecia areata and atopic dermatitis who showed significant improvement after treatment with baricitinib and corticosteroid ointment, suggesting their potential efficacy and safety.

In this study, Japanese patients with alopecia areata were found to have higher BMI and retinol intake, with retinol intake predicting severity of hair loss.

This study found that pediatric patients with severe alopecia areata showed significant improvement with systemic corticosteroids but typically experienced relapse within 4-5 months, also seeing an increase in weight percentiles.

In this retrospective study, researchers found that baricitinib was effective for treating moderate to severe alopecia areata, with response rates in 24 patients comparable to existing real-world data, and no new safety concerns were identified.

This study examined FAERS data and found an increasing trend in alopecia areata cases, with monoclonal antibodies most frequently linked to the condition.

This study examined 14 dogs with alopecia areata and found that oral ciclosporin was the most common treatment, with some dogs experiencing hair regrowth, though relapses were common when the medication was tapered or withdrawn.

This article summarizes a meeting of the American Board of Hair Restoration Surgery's Board of Directors to discuss future plans, but does not report new experimental results.

In this study, a strong positive correlation was found between clinician-reported and patient-reported measures for assessing eyebrow and eyelash hair loss in patients with severe alopecia areata, indicating high agreement during treatment with baricitinib over 52 weeks.

This study aimed to describe the distribution of eyebrow and eyelash hair loss in patients with varying severities of scalp hair loss from alopecia areata but does not report results.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

This article discusses ciliary madarosis as a transient condition secondary to IAC, emphasizing the value of physical and trichoscopic evaluations for diagnosis and prognosis; it does not report new clinical results.